Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,728.66
(
-0.23%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: nsomniyak post# 210841

Monday, 04/24/2017 5:45:09 PM

Monday, April 24, 2017 5:45:09 PM

Post# of 257268
Fresenius Kabi acquires AKRX for $34/sh in cash—a 35% premium to AKRX’s latest “unaffected” share price on 4/6/17 (#msg-130304273):

http://finance.yahoo.com/news/fresenius-kabi-acquire-akorn-205800399.html

The nominal deal value (including assumption of debt) is $4.75B. Due to international regulatory approvals, the deal is not expected to close until early 2018.

Fresenius Kabi is a wholly-owned subsidiary of the global healthcare giant, Fresenius SE & Co. KGaA (FRE.DE). (FMS, the dialysis company, is 31% owned by FRE.DE.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today